A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases
Richard J. Lee(La Roche College), Matthew R. Smith(Harvard University), M. Dror Michaelson(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), Carol Gurski(University of California, Los Angeles), David T. Miyamoto(Broad Institute), Malgorzata E. Smas(Harvard University), Philip J. Saylor(Massachusetts General Hospital), Wanling Xie(Dana-Farber Cancer Institute), Shyamala Maheswaran(Massachusetts General Hospital), Jonathan Goldin(UCLA Health), S. Michael Rothenberg(Pfizer (United States))
Cited by 74
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k